ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Just five weeks into gestation, a fetus can have its DNA collected during its mother’s routine Pap smear and accurately genotyped, according to a study (Sci. Transl. Med. 2016, DOI: 10.1126/scitranslmed.aah4661). The development holds promise for early genetic testing for thousands of birth defects. To obtain such information currently, pregnant women must undergo invasive and risky procedures such as chorionic villus sampling (CVS), a tissue analysis technique, at around 10–12 weeks’ gestation or amniocentesis at 16–18 weeks. Progress has also been made in the development of tests that detect snippets of fetal DNA in a mother’s blood. However, it can be difficult to generate an accurate picture of a fetal genome from these methods. Now, a team led by Chandni V. Jain, Sascha Drewlo, and D. Randall Armant of Wayne State University School of Medicine isolated placental cells known as trophoblasts from cervical canal swabs of 20 pregnant women at five to 19 weeks’ gestation. Trophoblasts carry fetal DNA, which the team was able to isolate and distinguish from the mothers’ DNA. They also showed that the fetal DNA quality is on par with DNA obtained through CVS or amniocentesis. The authors say tests can be developed for this source of fetal DNA that could identify single gene mutations, such as those responsible for some metabolic syndromes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X